表纸
市场调查报告书

沙眼披衣菌感染疾病 :全球临床实验趋势

Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018

出版商 GlobalData 商品编码 350907
出版日期 内容资讯 英文 73 Pages
订单完成后即时交付
价格
Back to Top
沙眼披衣菌感染疾病 :全球临床实验趋势 Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018
出版日期: 2018年12月31日内容资讯: 英文 73 Pages
简介

本报告提供沙眼披衣菌感染疾病相关临床研究最新趋势分析,提供您疾病·治疗方法概要,及G7与E7各国的临床实验状况,各地区、各阶段的进行状况,有潜力的赞助商,各企业及研究机关的研究进行状况,并汇整有潜力的药剂比较等资讯。

本报告概要

各地区的临床实验情形

  • 各国临床实验数量和平均实验人数
    • 前五名国家的临床实验数量; 亚太地区
    • 主要国家的临床实验数量; 欧洲
    • 主要国家的临床实验数量; 北美
    • 前五名国家的临床实验数量; 中东/非洲地区

G7各国的临床实验数量沙眼披衣菌感染疾病临床实验数量占感染疾病临床实验数量比率

Phase别临床实验数量: G7各国

G7各国的临床实验数量:Phase别

E7各国的临床实验数量沙眼披衣菌感染疾病临床实验数量占感染疾病临床实验数量比率

Phase别临床实验数量

  • Phase别的进展中临床实验数量

各进展状况临床实验数量

评估项目别临床实验数量

一定期间所采用的受验人数

赞助商类别的临床实验数量

有潜力的赞助商

临床实验主要参加企业 - 沙眼披衣菌感染疾病治疗药

有潜力的药剂

临床实验简介的基本资料

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GDHC5552CTIDB

GlobalData's clinical trial report, "Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018" provides an overview of Chlamydia trachomatis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia trachomatis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

  • Table of Contents 2
    • List of Tables 3
    • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
    • Clinical Trials and Average Enrollment by Country 8
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
      • Top Five Countries Contributing to Clinical Trials in Europe 12
      • Top Countries Contributing to Clinical Trials in North America 13
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
      • Top Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
    • In Progress Trials by Phase 24
  • Clinical Trials by Trial Status 25
  • Clinical Trials by End Point Status 26
  • Subjects Recruited Over a Period of Time 27
  • Clinical Trials by Sponsor Type 28
  • Prominent Sponsors 29
    • Top Companies Participating in Chlamydia trachomatis Infections Therapeutics Clinical Trials 31
  • Prominent Drugs 33
  • Clinical Trial Profile Snapshots 34
  • Appendix 71
    • Abbreviations 71
    • Definitions 71
    • Research Methodology 72
    • Secondary Research 72
    • About GlobalData 73
    • Contact Us 73
  • Source 73

List of Tables

  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Region, 2018* 7
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
  • Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 16
  • Chlamydia trachomatis Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Chlamydia trachomatis Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 20
  • Chlamydia trachomatis Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Chlamydia trachomatis Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Phase, 2018* 23
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 24
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Chlamydia trachomatis Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 28
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 30
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 32
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33

List of Figures

  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
  • Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2018* 16
  • Chlamydia trachomatis Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Chlamydia trachomatis Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Chlamydia trachomatis Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2018* 19
  • Chlamydia trachomatis Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 21
  • Chlamydia trachomatis Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 22
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Phase (%), 2018* 23
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 24
  • Chlamydia trachomatis Infections Therapeutics, Global, Clinical Trials by Trial Status, 2018* 25
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, by End Point Status, 2018* 26
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 27
  • Chlamydia trachomatis Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 28
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 29
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 31
  • Chlamydia trachomatis Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 33
  • GlobalData Methodology 72
Back to Top